Mavyret and Vosevi Will Join the Market of Oral Hep C Meds

October 2017

You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret (MAV-ih-reht) and Vosevi (voh-SEV-ee).

Mavyret (glecaprevir/pibrentasvir) will be a game changer.

It's the first hep C med that's approved to use for just 8 weeks for any type of hep C in most patients...instead of the usual 12 weeks.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Practice Prepare for a Pharmacy Inspection BEFORE It Happens
Influenza Be Ready to Answer Questions About the 2017-2018 Flu Vaccines
Beta-Blockers Expect Patients to Switch From Atenolol to a Better Beta-Blocker
Inhalers Think of ArmonAir as Similar to Flovent
Opioids Anticipate Quantity Limits on First-Time Opioid Rxs
Medication Errors Ensure Safety With Tacrolimus in Your Transplant Patients
Psychiatry Help Reduce Med Nonadherence in Patients With PTSD
Hair Loss Expect Many Women With Hair Loss to Try OTC Minoxidil
Hepatitis C Mavyret and Vosevi Will Join the Market of Oral Hep C Meds
Pediatrics Look Out for Kids Getting Meds for High Blood Pressure
Practice Get Our Special Report to Be Ready for the Next Disaster
Bowel Preps Help Patients Use Bowel Preps Safely and Effectively